HIF-1 alpha gene therapy (Sanofi Genzyme)

N/A

Report date: 2023/10/26 16:02:20

Base Information

Drug NameHIF-1 alpha gene therapy (Sanofi Genzyme)
Drug Alias NameCardiovascular disease gene therapy - Sanofi GenzymeAd2/HIF-1α/VP16Ad2/HIF-1 alphaAd2/HIF-1a
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adenoviral vector > Ad2 vector
Mechanisms of ActionGene transferenceAngiogenesis inducersHypoxia-inducible factor 1 alpha inhibitors
TargetsHypoxia-inducible factor 1 alpha
Therapy Area/IndicationsPeripheral Vascular DiseasesIntermittent ClaudicationAtherosclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesJohns Hopkins UniversityShanghai Sunway Bio Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenzyme Corp
Active IndicationsN/A
Inactive IndicationsPeripheral Vascular DiseasesIntermittent ClaudicationAtherosclerosis

Other Information

ATC CodeN/A
Related LinksN/A